薬学部

Pharmacology, Toxicology and Pharmaceutical Science

1. Rat 100%
2. Pharmacokinetic 77%
3. Malignant Neoplasm 59%
4. Adverse Event 47%
5. Neoplasm 37%
6. Vancomycin 35%
7. Cytotoxicity 33%
8. ABCG2 32%
9. Diseases 31%
10. Nanoparticle 31%
11. Liver Cell Carcinoma 29%
12. Helicobacter Pylori 27%
13. Enzymes 26%
14. Messenger RNA 25%
15. microRNA 24%
16. Anticarcinogen 24%
17. Fullerene Derivative 23%
18. Inflammation 22%
19. Infection 21%
20. Adverse Drug Reaction 21%
21. Clinical Trial 20%
22. Interferon 19%
23. Chemotherapy Regimens 19%
24. Anti-Inflammatory Drug 19%
25. Breast Cancer 19%
26. Lipid 18%
27. P-Glycoprotein 18%
28. Retrospective Study 18%
29. Multiple Myeloma 18%
30. Liposome 17%
31. Therapeutic Drug Monitoring 17%
32. Chronic Hepatitis C 17%
33. Antioxidant 17%
34. High Performance Liquid Chromatography 17%
35. Pharmacodynamics 16%
36. Cytochrome P450 16%
37. Diethylstilbestrol 16%
38. Receptor 16%
39. Drug Resistance 16%
40. Acute Kidney Failure 15%
41. Observational Study 15%
42. Peptide 15%
43. Albumin 14%
44. CYP3A4 14%
45. Antiinfective Agent 14%
46. Ornithine Decarboxylase 13%
47. Therapeutic Effect 13%
48. 12-O-Tetradecanoylphorbol-13-Acetate 13%
49. Amino Acid 13%
50. Flavonoid 13%
51. IC50 13%
52. Tablet 13%
53. Cytokine 13%
54. Mouse Model 12%
55. Intestine Flora 12%
56. Nitric Oxide 12%
57. Cohort Study 12%
58. Drug Discovery 12%
59. Colon Carcinoma 12%
60. Reactive Oxygen Metabolite 12%
61. Copolymer 12%
62. Monotherapy 12%
63. Cataract 12%
64. Randomized Controlled Trial 12%
65. Chronic Kidney Failure 12%
66. Acetylcholine 12%
67. Superoxide Dismutase 12%
68. Indometacin 11%
69. Estrogen 11%
70. Linezolid 11%
71. Drug Development 11%
72. Methemoglobin 11%
73. Biological Marker 11%
74. Liver Fibrosis 11%
75. Glucose 10%
76. Minimum Inhibitory Concentration 10%
77. Transcription Factor Nrf2 10%
78. Carbon Monoxide 10%
79. Rheumatoid Arthritis 10%
80. Inflammatory Arthritis 10%
81. Bioavailability 10%
82. Antibiotics 10%
83. Protein Kinase C 10%
84. Hepatitis C Virus 10%
85. Non-Steroidal Anti-Inflammatory Drug 10%
86. Hypertension 10%
87. Antiinflammatory Activity 10%
88. Non Small Cell Lung Cancer 10%
89. Rat Model 10%
90. Antimicrobial Agent 10%
91. Hydrogen Sulfide 10%
92. Effusion 9%
93. Polypeptide 9%
94. Combination Therapy 9%
95. Silicon Dioxide 9%
96. Carcinogenesis 9%
97. Nonalcoholic Fatty Liver 9%
98. Dexamethasone 9%
99. Metronidazole 9%
100. Western Blot 9%

Keyphrases

1. Japan 72%
2. Poly(N-isopropylacrylamide) (PNIPAM) 39%
3. Vancomycin 37%
4. Acetylcholine 28%
5. Methyl 25%
6. Apoptosis Induction 25%
7. Meta-analysis 24%
8. Thermoresponsive 24%
9. NF-B 23%
10. Inhibitory Effect 23%
11. Interferon-α (IFN-α) 23%
12. Gut Microbiota 20%
13. 95% Confidence Interval 19%
14. Cytotoxicity 18%
15. Thermoresponsive Polymer 17%
16. Apoptosis 17%
17. Multicenter Retrospective Study 17%
18. Liquid Chromatography-tandem Mass Spectrometry (LC-MS/MS) 17%
19. Phosphorylation 17%
20. Adverse Events 17%
21. Acetate 16%
22. Silica Beads 16%
23. Macrophages 16%
24. Japanese Patients 16%
25. Pharmacokinetics 16%
26. Glycosphingolipids 16%
27. Breast Cancer Resistance Protein 15%
28. Helicobacter Pylori (H. pylori) 15%
29. Stationary Phase 15%
30. Cell Proliferation 15%
31. MicroRNA 15%
32. Fullerene Derivatives 15%
33. Risk Factors 15%
34. Syncytiotrophoblast 15%
35. Nuclear Factor Erythroid 2-related Factor 2 (Nrf2) 14%
36. Area under the Concentration-time Curve 14%
37. Temperature-responsive Chromatography 14%
38. Gene Expression 14%
39. Therapeutic Drug Monitoring 14%
40. Hepatocellular Carcinoma 14%
41. Temperature-responsive 14%
42. Nanoparticles 13%
43. Odds Ratio 13%
44. Acetylcholine Release 13%
45. Optically Active 13%
46. MRNA Expression 13%
47. Chronic Kidney Disease 13%
48. Lipase-catalyzed 13%
49. High-performance Liquid Chromatography 13%
50. Chronic Hepatitis C 13%
51. M Cells 13%
52. Anti-inflammatory Activity 12%
53. Nuclear Magnetic Resonance 12%
54. Flavonoids 12%
55. T Cells 12%
56. Cytochrome P450 3A4 (CYP3A4) 12%
57. Cytochrome P450 (CYP450) 12%
58. Multiple Myeloma 12%
59. Coffee 12%
60. Liver 12%
61. HL-60 Cells 11%
62. Polymer Modified 11%
63. Phorbol 12-myristate 13-acetate 11%
64. Escherichia Coli 11%
65. Acute Kidney Injury 11%
66. Nicotinic Acetylcholine Receptor (nAChR) 11%
67. Chinese Hamster Ovary Cells 11%
68. Racemic 11%
69. Polysaccharides 11%
70. Drug Interactions 11%
71. Epidermis 11%
72. Liposomes 11%
73. Copolymer Brushes 11%
74. Eosinophils 10%
75. Genetic Variants 10%
76. Oxidative Stress 10%
77. Overexpression 10%
78. Cancer Cells 10%
79. Inhibitory Activity 10%
80. P-glycoprotein (P-gp) 10%
81. Synthetic Study 10%
82. Cataract 10%
83. Diethylstilbestrol 10%
84. Interleukin-1β 10%
85. Stereochemistry 10%
86. Minimum Inhibitory Concentration 10%
87. Albumin 10%
88. Chemoenzymatic Synthesis 10%
89. Human Hepatoma Cells 10%
90. Signal Transducer 10%
91. Reactive Oxygen Species 10%
92. Molar Ratio 10%
93. Myeloma Cells 9%
94. D-galactose (D-gal) 9%
95. Mouse Model 9%
96. Nonalcoholic Steatohepatitis 9%
97. Tumor 9%
98. Alcohol 9%
99. ATP Binding Cassette Subfamily G Member 2 (ABCG2) 9%
100. Protective Effect 9%